US Biobanks Market Size Likely to Surpass at a CAGR of 7.23% By 2034
Market Size and Growth
As per the US Biobanks Market size analysis conducted by the BRI team, the US biobanks market is expected to record a CAGR of 7.23% from 2025 to 2034. In 2025, the market size was USD 19.67 Billion. By 2034, the valuation is anticipated to reach USD 37.03 Billion.
Overview
As per the industry experts at BRI, the U.S. biobanks market is likely to witness a staggering CAGR during the forecast period. This shift can be attributed to the transition from building sample repositories to extending support for precision medicine pipelines, which aim to integrate stem cell therapies, multi-omics workflows, and proteomics. Plus, appropriate regulations, such as the U.S. FDA’s January 2025 draft guidance on donor eligibility, are curtailing clinical uncertainty and fastening adoption in pharmaceutical and hospital settings. The demand is further accelerated by private and public funding for pandemic preparedness, hospital uptake of the cord-blood services, and a rise in adoption of AI-based quality analytics.
Key Trends & Drivers
- Innovations in Regenerative Medicine to Determine Growth: Various breakthroughs in the form of Cedars-Sinai’s cardiosphere-derived cells for Duchenne muscular dystrophy do show the way in which a single type of cell could address multiple therapeutic paths. The gene-edited progenitor cells for ALS require biobanks to ensure that their genes stay stable and the cells remain healthy. The EMBODY program from ARPA-H does demand infrastructure that is capable of supporting complex immune-cell reprogramming. The above-mentioned shifts are pushing the U.S. biobank market toward exponential growth.
- Rising Incidences of Chronic Diseases to Catalyze the Market: An increase in chronic diseases does create a greater need for biological samples for precision healthcare research and personalized medicine. The biobanks make provisions for essential biological samples for studying disease mechanisms, developing new treatments, and conducting clinical trials, thereby marking them imperative for researchers and pharmaceutical companies that emphasize chronic ailments such as cardiovascular disorders, cancer, and neurological diseases.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 19.67 Billion |
| Projected Market Size in 2034 | USD 37.03 Billion |
| Market Size in 2024 | USD 18.34 Billion |
| CAGR Growth Rate | 7.23% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Product & Services, Biospecimen, Type, Application and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Country Scope | US |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
SWOT Analysis
- Strengths: Strong government funding, academic research initiatives, and partnerships with the pharma companies do support the expansion of biobanks. Large-scale adoption of advanced technologies such as automation, AI, and cloud systems improves data accessibility and operational efficiency. Biobanks do store numerous types of specimens, inclusive of solid tissues, blood products, nucleic acids, and cell lines.
- Weaknesses: Higher costs associated with storage of biospecimen samples do pose a major challenge. There could also be certain misconceptions regarding biobanking due to inadequate knowledge. Moreover, ascertaining robust security and management of the vast datasets that biobanks generate is complex.
- Opportunities: Expansion of virtual biobanks does offer potential for more accessible and efficient research platforms. Role of biobanks in the identification of biomarkers, disease diagnosis, and precision medicine programs does create notable opportunities for growth. Rise in the frequency of collaboration among universities, private firms, and government agencies could accelerate disease research and drug discovery. Extensive research is being conducted regarding the usage of cord blood for several health benefits, thereby driving the demand for biobanks.
- Threats: The navigation of complex ethical regulations and guidelines revolving around the privacy of specimen data could hinder the growth of the market. This is a probable threat to the U.S. biobanks market.
List of the prominent players in the US Biobanks Market:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- QIAGEN
- Hamilton Company
- Tecan Trading AG
- ViaCord (Revitty)
- Cryo-Cell
- BioCision LLC
- Icbiomedical
- Charles River Laboratories
- Azenta US Inc.
- Stemcell Technologies
- Biovault Family
- LabVantage Solutions Inc.
- Precision Cellular Storage Ltd.
- Others
The US Biobanks Market is segmented as follows:
By Product & Services
- Products
- Biobanking Equipment
- Temperature Control Systems
- Freezers & Refrigerators
- Cryogenic Storage Systems
- Thawing Equipment
- Incubators & Centrifuges
- Alarms & Monitoring Systems
- Accessories & Other Equipment
- Biobanking Consumables
- Laboratory Information Management Systems
- Services
- Biobanking & Repository
- Lab Processing
- Qualification/Validation
- Cold Chain Logistics
By Biospecimen
- Human Tissues
- Organs
- Stem Cells
- Adult Stem Cells
- Embryonic Stem Cells
- IPS Cells
By Type
- Physical/Real Biobanks
- Tissue Biobanks
- Population-based Biobanks
- Genetic (DNA/RNA)
- Disease-based Biobanks
- Virtual Biobanks
By Application
- Therapeutics
- Drug Discovery & Clinical Research
- Clinical Diagnostics
[embedsocial_reviews id=”d4ae80cffae3d938f997111953699a733c8e6f99″]